Helix BioPharma Files Q3 2025 Financials, Advances Innovative Cancer Pipeline
December 15, 2025 — Helix BioPharma files Q3 2025 financial statements while advancing innovative cancer treatments including L-DOS47 for NSCLC. Clinical-stage oncology company updates investors on pipeline progress.